Click Here to
News, Updates,
& More
Stay Up
to Date

From the Literature

1: Sitagliptin, a DPP-4 Inhibitor, Reduces the Incidence of Acute GVHD After Stem-Cell Transplant
2: Pembrolizumab Shows Long-Term Benefits in Patients with Metastatic Colorectal Cancer and MSI-H or dMMR
With commentaries by Robert J. Ignoffo, PharmD, FASHP, FCSHP, FHOPA
  • Tisagenlecleucel Shows High, Durable Responses in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
  • Olaparib Maintenance Extends Progression-Free Survival in Advanced Ovarian Cancer
  • Ibrutinib Superior to Standard Chemoimmunotherapy in Older Patients with Chronic Lymphocytic Leukemia
  • How Oncology Pharmacists Can Enhance Patient Quality of Care
  • Metastasis-Free Survival for Prostate Cancer Longerwith Apalutamide than with Placebo
  • Nivolumab plus Ipilimumab Combination Improves Overall Survival in Untreated Renal-Cell Carcinoma
  • Alectinib Shows Superior Outcomes versus Crizotinib in NSCLC with ALK Mutation
  • Durvalumab Use After Chemoradiotherapy Prolongs Progression-Free Survival in Stage III NSCLC
  • Olaparib Improves Progression-Free Survival in Metastatic Breast Cancer with BRCA Mutation
  • Adding Antiandrogen to Radiation Therapy Extends Survival in Relapsed Prostate Cancer
  • Venetoclax plus Rituximab an Attractive Treatment Option for Relapsed or Refractory CLL
  • Aggressive Local Consolidative Therapy Shows Benefit in Patients with Oligometastatic Non–Small-Cell Lung Cancer
  • Lutetium-177-Dotatate Extends Progression-Free Survival in Patients with Midgut Neuroendocrine Tumors
  • Inotuzumab Ozogamicin Shows Benefit in Acute Lymphoblastic Leukemia
  • Adding Daratumumab to Combination Therapy Improves Progression-Free Survival in Patients with Multiple Myeloma
  • Two-Drug Combination Shows Promise for Recurrent Small-Cell Lung Cancer
  • Ricolinostat Shows Promise in Patients with Relapsed or Refractory Multiple Myeloma
  • Afatinib Superior to Gefitinib as First-Line Treatment for EGFR Mutation–Positive NSCLC
  • Combination Chemotherapy plus Radiation Prolongs Survival in Low-Grade Glioma
  • Acalabrutinib Demonstrates Efficacy and Safety in Relapsed CLL
  • Personalizing Therapy for Patients with Multiple Myeloma
  • Targeting BCL2 with Venetoclax in Patients with Relapsed CLL
  • Acalabrutinib Demonstrates Efficacy and Safety in Relapsed CLL
  • Atezolizumab Shows Durable Response, Tolerability in Urothelial Carcinoma
Page 1 of 4
Results 1 - 10 of 33